Bidding 9-13 Oct 2025, price band ₹461–485, lot 30 shares.
| Date | GMP (₹) | Est. Listing Price (₹) | Est. Listing Gain |
|---|---|---|---|
| 15 Oct | ₹120 | ₹605 | 24.74% |
| 14 Oct | ₹151 | ₹636 | 31.13% |
| 13 Oct | ₹128 | ₹613 | 26.39% |
| 12 Oct | ₹127 | ₹612 | 26.19% |
| 11 Oct | ₹96 | ₹581 | 19.79% |
| 10 Oct | ₹110 | ₹595 | 22.68% |
| 9 Oct | ₹111 | ₹596 | 22.89% |
| 8 Oct | ₹100 | ₹585 | 20.62% |
| 7 Oct | ₹98 | ₹583 | 20.21% |
| 6 Oct | ₹80 | ₹565 | 16.49% |
| 5 Oct | ₹80 | ₹565 | 16.49% |
| 4 Oct | ₹68 | ₹553 | 14.02% |
| 3 Oct | ₹60 | ₹545 | 12.37% |
| 2 Oct | ₹0 | ₹485 | 0.00% |
| 1 Oct | ₹0 | ₹485 | 0.00% |
After allotment
| Category | Times | Est. Allotment Chances* |
|---|---|---|
| HNIs (Total) | 102.66🔥 | 0.97% |
| bHNI | 117.77🔥 | 0.85% |
| sHNI | 72.43🔥 | 1.4% |
| QIBs | 137.09🔥 | - |
| Retail | 36.82🔥 | 2.7% |
| Employees | 17.49🔥 | 5.7% |
*Rough estimate: 1 ÷ times subscribed. Retail and HNI allotment is by lottery, so actual odds depend on the number of applications.
Rubicon Research Limited, established in 1999, is a pharmaceutical formulation company focused on innovation through research and development, with a strong presence in regulated markets, particularly the United States.The company operates two R&D facilities inspected by the USFDA (United States Food and Drug Administration) in India and Canada, along with two manufacturing plants in India. It holds accreditations from global regulatory bodies like the USFDA, WHO-GMP (World Health Organization – Good Manufacturing Practices), and Health Canada. Rubicon’s portfolio includes 55 commercialized formulations in the U.S., highlighting its focus on regulated markets.